Revolution Medicines (RVMD) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Revolution Medicines is expected to report its Q2 2025 earnings on August 6th, with analysts predicting a loss of ($1.14) per share and $0.50 million in revenue.
• The stock price of Revolution Medicines has decreased by 0.7% and the company has a market cap of $6.89 billion, with current stock prices opening at $37.01.
• Analysts maintain a consensus rating of "Buy" for Revolution Medicines, with an average target price of $68.91 despite some recent adjustments by brokerage firms.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($1.14) per share and revenue of $0.50 million for the quarter.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same quarter last year, the business posted ($0.70) EPS. On average, analysts expect Revolution Medicines to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Revolution Medicines Stock Down 1.7%

NASDAQ RVMD traded down $0.64 during trading hours on Friday, hitting $36.63. The company's stock had a trading volume of 978,549 shares, compared to its average volume of 1,474,059. The stock has a fifty day moving average of $38.64 and a 200 day moving average of $38.89. Revolution Medicines has a twelve month low of $29.17 and a twelve month high of $62.40. The firm has a market capitalization of $6.82 billion, a P/E ratio of -9.16 and a beta of 1.16.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in RVMD. Millennium Management LLC grew its position in Revolution Medicines by 681.8% in the first quarter. Millennium Management LLC now owns 156,353 shares of the company's stock valued at $5,529,000 after purchasing an additional 136,353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Revolution Medicines by 14.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company's stock valued at $10,615,000 after acquiring an additional 37,345 shares during the period. Finally, Nextech Invest Ltd. grew its position in shares of Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after acquiring an additional 1,304,347 shares during the period. Institutional investors own 94.34% of the company's stock.

Analysts Set New Price Targets

RVMD has been the topic of several analyst reports. The Goldman Sachs Group initiated coverage on shares of Revolution Medicines in a report on Tuesday, July 15th. They issued a "buy" rating and a $65.00 target price on the stock. Wedbush reiterated an "outperform" rating and issued a $73.00 target price (up from $67.00) on shares of Revolution Medicines in a report on Tuesday, June 24th. Oppenheimer increased their target price on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and issued a $72.00 target price (down from $73.00) on shares of Revolution Medicines in a report on Wednesday, May 14th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $57.00 target price on shares of Revolution Medicines in a report on Tuesday, June 24th. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $68.91.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.